HelmyMGuirgisMD

Oncology • Dana Point, CA

Cutaneous Lymphoma, Hematologic Oncology

Physician

Join to view full profile

Dr. Guirgis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Guirgis' full profile

Already have an account?

Office
24806 Sea Crest Dr
Dana Point, CA 92629
Phone+1 949-306-7157

Fax+1 949-493-7775
Is this information wrong?

Summary

Drug Costs vs Probability of Survival in Lung Cancer: Impact of Dosage, Duration

Abstract: Clinical guidelines and pathways recommend use of immune checkpoint inhibitors (ICI) in first- and second-line treatment of advanced/metastatic non-sm

The impact of PD-L1 on survival and value of the immune check point inhibitors i

The impact of programmed death receptor-ligand1 (PD-L1) on costs and value of the immune check point inhibitors (ICPI) has received minimal attention. Objective

Education & Training

University of California (Irvine)Fellowship, Hematology and Medical Oncology, 1979 - 1980
City of Hope National Medical CenterFellowship, Hematology and Medical Oncology, 1978 - 1979
Mount Sinai Hospital Medical Center of ChicagoResidency, Internal Medicine, 1976 - 1978
Creighton University School of Medicine (Omaha)Internship, Internal Medicine, 1975 - 1976
Creighton University School of MedicineClass of 1975

Certifications & Licensure

IL State Medical License 1976 - Present
CA State Medical License 1978 - 2025
CT State Medical License 2003 - 2003
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

13 citations
The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective.
Helmy M. Guirgis> ;Journal for Immunotherapy of Cancer. 2018 Feb 20
12 citations
The value of anticancer drugs in metastatic castrate-resistant prostate cancer: economic tools for the community oncologist.
Helmy M. Guirgis> ;The Journal of Community and Supportive Oncology. 2015 Oct 1
8 citations
Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation?
Helmy M. Guirgis> ;Journal of Oncology Practice. 2012 Jul 1
1 citations
Cutting the cost of cancer care.
Helmy M. Guirgis> ;Gastrointestinal Cancer Research. 2009 Jul 1
Join now to see all

Lectures

Costs and hazard ratios of commonly used drugs in advanced/metastatic lung cancer at Cancer Free Foundation, Dana Point, California.
2019 ASCO Annual Meeting - 6/1/2019

Committees

Member, Tunor Boards in various hospitals in Orange County,CA 1985 - 2013

Research History

Development of methodology to evaluate value of anticancer drugsAuthored various manuscripts and abstracts on cost of anticancer drugs and survival.1995 - Present